Ipsen Pharma: Ipsen's Iqirvo® receives U.S. FDA acceler

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

Related Keywords

Paris , France General , France , Macau , United States , China , United Kingdom , Washington , Hong Kong , Taiwan , American , Christelle Huguet , Rachel Reiff , Kris Kowdley , Nicolas Bogler , Anna Gibbins , Amy Wolf , Carol Roberts , Clin Gastroenterol Hepatol , Ipsen Euronext , Ipsen Pharmaceuticals Inc , Regulatory Agency , Liver Institute , Head Of Research , Drug Administration , Fibrotic Liver Disease Consortium Investigators , Ipsen Pharmaceuticals , Newborn Development , European Medicines Agency , Executive Vice President , New England Journal , Important Safety Information , Liver Institute Northwest , Executive President , United Kingdom Medicines , Induced Liver Injury , Adverse Event , Reproductive Potential , Prescribing Information , Breakthrough Therapy Designation , Rare Disease , Sponsored Leveli American Depositary Receipt , French Autorit , Des March , Universal Registration Document , Primary Biliary , Liver Disease Consortium , Increasing Prevalence , Primary Biliary Cholangitis , Reduced Mortality With , Clin Gastroenterol , Ihr Portfolio ,